TICKERNERD
Menu
CCCCBasic Materials · Specialty Chemicals

CC Stock Forecast: The Chemours Co. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$15
−0.27% on the day

The 9 Wall Street analysts covering The Chemours Co. hold a median 12-month price target of $18 — +19.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 11 Sept 2026 — in the upper half.

Market cap
$2.3B
Ticker Nerd rank
61 / 100
Median analyst target
$18
Analysts covering
9
Revenue$1.6B−1.5% y/y
Operating income−$210.0M
Net income−$274.0M
Free cash flow$114.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
+2.1%
YTD
+29.3%
1Y
−8.4%
From 52W high
−45.7%
From 52W low
+45.5%
$10
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores The Chemours Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
61 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
91
Issuance
86
Value
86
Momentum
61
Quality
45
Growth
42
Size
34
Volatility
32
Revisions
30

Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.

Revisions (30): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CCHigh $24Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
4 Buy5 Hold0 Sell
Low $15Median $18High $24

The green dot is the last close — the median target sits +19.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
13 Aug 2026BMO CapitalMaintainsOutperform$26 → $18
13 Aug 2026JP MorganMaintainsNeutral$22 → $15
10 Aug 2026UBSDowngradeNeutral$29 → $18
6 Aug 2026RBC CapitalMaintainsOutperform$26 → $22
6 Aug 2026Truist SecuritiesMaintainsBuy$30 → $24
1 July 2026MizuhoMaintainsOutperform—
1 July 2026MizuhoMaintainsOutperform$30 → $25
21 May 2026JP MorganMaintainsNeutral—
11 May 2026Morgan StanleyMaintainsEqual-Weight—
11 May 2026RBC CapitalMaintainsOutperform—
8 May 2026UBSMaintainsBuy—
28 Apr 2026Truist SecuritiesMaintainsBuy—
9 Apr 2026Truist SecuritiesMaintainsBuy—
9 Apr 2026UBSMaintainsBuy—
5 Mar 2026MizuhoMaintainsOutperform—
25 Feb 2026Goldman SachsMaintainsNeutral—
23 Feb 2026BMO CapitalMaintainsOutperform—
23 Feb 2026JP MorganMaintainsNeutral—
23 Feb 2026Morgan StanleyMaintainsEqual-Weight—
23 Feb 2026UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, The Chemours Co. returned −8.4% against +17.5% for the S&P 500, dividends included.

CC vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26CCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−24.1%
Analysts raising
0
Analysts cutting
6
Fundamentals

The Chemours Co. (CC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
67.8×

Cheaper than 10% of US stocks

Price / sales
0.4×

Cheaper than 85% of US stocks

Price / book
−47.4×

Cheaper than 99% of US stocks

EV / EBITDA
11.8×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
−1.5%

Higher than 25% of US stocks

Earnings growth (YoY)
−1.5%

Higher than 34% of US stocks

Gross margin
18.0%

Higher than 18% of US stocks

Operating margin
1.1%

Higher than 47% of US stocks

Net margin
−5.2%

Higher than 24% of US stocks

Returns & dividend
Return on equity
−319.4%

Higher than 5% of US stocks

Return on assets
1.4%

Higher than 54% of US stocks

Dividend yield
2.3%

Higher than 51% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

The Chemours Co. (CC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • The Chemours Co. has a market value of $2.3B and an enterprise value of $5.7B.

  • Revenue in the twelve months to 30 June 2026: $5.8B. The latest quarter shrank 1.5% year on year.

  • Net income over the same four quarters: −$305.0M, a −5.3% net margin.

  • Free cash flow in the twelve months to 30 June 2026: $218.0M.

  • The Chemours Co. spent $54.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 150.5M.

  • Trailing P/E: 67.8×; forward P/E: 7.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.34%, paying out 556% of earnings.

  • The Chemours Co. employs 5,700 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
CCThe Chemours Co.$2.3B
61
IOSPInnospec, Inc.$2.3B
89
MTXMinerals Technologies, Inc.$2.1B
70
NGVTIngevity Corp.$2.5B
99
HWKNHawkins, Inc.$2.6B
70
WDFCWD-40 Co.$2.6B
71
KWRQuaker Houghton$2.7B
93

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own The Chemours Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CC news & analysis

Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination

Business Wire · 10 Sept 2026neutral

Baron & Budd announced a $380 million settlement involving DuPont, The Chemours Company, and Corteva to resolve PFAS contamination claims brought by 11 North Carolina public entities, including several counties, municipalities, and the Lower Cape Fear Water and Sewer Authority.

Why it matters — The settlement resolves PFAS-related litigation involving Chemours as one of the settling companies, reducing legal uncertainty for CC shareholders.

Chemours, DuPont, Corteva settle North Carolina 'forever chemicals' claims for $455 million

Reuters · 10 Sept 2026neutral

Chemours, DuPont and Corteva agreed to a $455 million settlement with North Carolina and 11 local entities over PFAS contamination claims linked to Chemours' Fayetteville Works plant and other historical discharges.

Why it matters — This resolves PFAS-related liabilities involving Chemours' operations, clarifying its ongoing environmental exposure in North Carolina.

Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina

PRNewsWire · 10 Sept 2026neutral

The Chemours Co., DuPont and Corteva reached an agreement resolving PFAS-related claims in North Carolina, covering litigation brought by the state and 11 local entities regarding historical discharges from Fayetteville Works and other PFAS contamination claims. Total settlement payments are $455 million over 15 years, with Chemours' 50% share being approximately $180 million on a net present value basis, which is covered by existing accruals.

Why it matters — This resolves a significant PFAS-related litigation matter for Chemours, with the associated settlement payments already covered by existing accruals, providing clarity on a key legal overhang.

Chemours (CC) Up 7.5% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 3 Sept 2026positive

Chemours (CC) reported earnings 30 days ago, and since that earnings report the stock has risen 7.5%. The article asks what may come next for the stock following that move.

Why it matters — A CC watcher would want to assess whether the stock's post-earnings advance reflects continuing momentum or a potential pause.

Chemours Publishes 2025 Sustainability Report Highlighting Progress on Climate, Emissions Reduction, and Responsible Manufacturing

PRNewsWire · 25 Aug 2026positive

Chemours announced the release of its 2025 Sustainability Report, which details progress on climate, emissions reduction, and responsible manufacturing across its Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials segments.

Why it matters — The report signals Chemours' commitment to sustainability initiatives and transparent reporting, which may be relevant to investors tracking the company's environmental performance and operational practices.

FAQ

Frequently asked questions about CC stock

What is the CC stock price forecast for 2026-2027?

The 9 Wall Street analysts covering The Chemours Co. have a median 12-month price target of $18, with estimates ranging from $15 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CC stock a buy right now?

Of the 9 analysts covering The Chemours Co., 4 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks The Chemours Co. 61 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CC?

As at 11 Sept 2026, The Chemours Co. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).

Will CC stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +19.8% from the last close, and Ticker Nerd's factor model ranks The Chemours Co. 61 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CC stock forecast for 2030?

No analyst covering The Chemours Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $24 over the next 12 months.

How has CC stock performed over the past year?

The Chemours Co. returned -8.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does The Chemours Co. do?

The Chemours Company is a global chemistry company that develops and supplies industrial and specialty chemical products for a wide range of end markets. Its core business is organized into Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, each serving distinct applications across refrigeration and air conditioning, coatings, plastics, transportation, semiconductors, electronics, and general industrial uses.

What is the latest news on CC?

The most recent item we track (Business Wire, 10 Sept 2026): "Baron & Budd Secures $380 Million Settlement With DuPont, Chemours, and Corteva Over North Carolina PFAS Contamination". Baron & Budd announced a $380 million settlement involving DuPont, The Chemours Company, and Corteva to resolve PFAS contamination claims brought by 11 North Carolina public entities, including several counties, municipalities, and the Lower Cape Fear Water and Sewer Authority.

Company

About The Chemours Co.

The Chemours Company is a global chemistry company that develops and supplies industrial and specialty chemical products for a wide range of end markets. Its core business is organized into Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials, each serving distinct applications across refrigeration and air conditioning, coatings, plastics, transportation, semiconductors, electronics, and general industrial uses. The company’s product portfolio includes refrigerants, thermal management solutions, propellants, blowing agents, specialty solvents, titanium dioxide pigments, and advanced fluoropolymer materials. These materials are used as key inputs in manufacturing and performance-driven applications, supporting customers that need durability, efficiency, brightness, opacity, and thermal control. Chemours serves a global customer base across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa, making it an important supplier within the specialty chemicals market.

CEO Ms. Denise M. Dignam · 5,700 employees · United States · https://www.chemours.com